Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.

  Glancy Binkow & Goldberg Announces Lead Plaintiff Deadline In The Class
  Action Lawsuit Against AVEO Pharmaceuticals, Inc.

Business Wire

LOS ANGELES -- June 17, 2013

Glancy Binkow & Goldberg LLP announces that all purchasers of the securities
of AVEO Pharmaceuticals, Inc. (“AVEO” or the “Company”) (NASDAQ: AVEO) between
January 3, 2012 and May 1, 2013 (the “Class Period’) have until July 8, 2013
to file a motion to be appointed as lead plaintiff in the shareholder lawsuit
filed in the United States District Court for the District of Massachusetts.
Investors who have losses of $200,000 or more are encouraged to contact the
firm for information concerning a lead plaintiff position in the shareholder
lawsuit.

A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW &
GOLDBERG LLP. PLEASE CONTACT US AT (212) 682-5340, TOLL-FREE AT (888)
773-9224, OR AT SHAREHOLDERS@GLANCYLAW.COM. IF YOU INQUIRE BY EMAIL PLEASE
INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED.

AVEO engages in discovering, developing, and commercializing targeted cancer
therapies. The Complaint alleges that defendants issued materially false and
misleading statements throughout the Class Period regarding the Phase III
trial design and results for the Company’s drug Tivopath, or tivozanib, for
the treatment of advanced kidney cancer. Specifically, defendants
misrepresented or failed to disclose: (1) that the FDA had recommended that
the Company conduct an additional Phase III trial due to adverse trends in the
Company’s first Phase III trial; (2) the 25% higher rate of death associated
with tivozanib therapy compared to the control drug, sorafenib; (3) that
almost 90% of the patients studied in TIVO-1 were enrolled from sites in
Central and Eastern Europe with inconsistent treatment patterns from those in
the U.S.; and (4) as a result of the foregoing, the Company’s statements were
materially false and misleading at all relevant times.

To be a member of the Class you need not take any action at this time; you may
retain counsel of your choice or take no action and remain an absent member of
the Class. To learn more about this action or if you purchased AVEO stock
prior to the Class Period and have any questions concerning this Notice or
your rights or interests with respect to these matters, please contact Michael
Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East,
Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or
contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd
Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to
shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contact:

Glancy Binkow & Goldberg LLP, Los Angeles, CA
Michael Goldberg, 888-773-9224
or
Glancy Binkow & Goldberg LLP, New York, NY
Gregory Linkh, 212-682-5340
shareholders@glancylaw.com
www.glancylaw.com
 
Press spacebar to pause and continue. Press esc to stop.